Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trialAndrés Poveda, Nicolas Pécuchet, Anne Floquet et al.|The Lancet Oncology|2021Cited by 412
Uterine serous carcinomaGiorgio Bogani, Bradley J. Monk, Alice Indini et al.|Gynecologic Oncology|2021Cited by 158
Endometrial carcinosarcomaGiorgio Bogani, Bradley J. Monk, Isabelle Ray‐Coquard et al.|International Journal of Gynecological Cancer|2022Cited by 95
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian CancerAmit M. Oza, Daniela Matei, Ursula A. Matulonis et al.|Clinical Cancer Research|2019Cited by 90
Epigenetic resensitization to platinum in recurrent, platinum-resistant ovarian cancer (OC) using guadecitabine (SGI-110), a novel hypomethylating agent (HMA): Results of a randomized phase II study.Ursula A. Matulonis, Daniela Matei, Amit M. Oza et al.|Journal of Clinical Oncology|2016Cited by 8